Intensity Therapeutics appoints Joseph Talamo as CFO; John Wesolowski returns to Controller role

INTENSITY THERAPEUTICS, INC.

Joseph Talamo appointed CFO effective Dec 11, 2023; replaces interim CFO John Wesolowski.
Talamo brings 25+ years biopharma experience; previously CFO of HiberCell and Caladrius Biosciences.
Compensation: $370k base salary, 35% target bonus, 80,000 options at $6.88 exercise price (4-year vest).
Wesolowski remains as Principal Accounting Officer and Controller.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

John Wesolowski

Chief Financial Officer

INTS · INTENSITY THERAPEUTICS, INC.

Effective: 2023-12-11
Successor: Joseph Talamo
Filed: December 12, 2023, 6:59 PM ET

With the appointment of Mr. Talamo as the Company’s new Chief Financial Officer, Mr. Wesolowski will no longer serve in this capacity but will continue on as the Company’s Principal Accounting Officer and Controller.

Appointed

Joseph Talamo

Chief Financial Officer

INTS · INTENSITY THERAPEUTICS, INC.

Effective: 2023-12-11
Filed: December 12, 2023, 6:59 PM ET

On December 11, 2023, Intensity Therapeutics (the “Company”), appointed Joseph Talamo to serve as the Chief Financial Officer of the Company effective December 11, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John Wesolowski changed role as Chief Financial Officer at INTENSITY THERAPEUTICS, INC..

Action: ceased serving as interim
Role: Chief Financial Officer

Exact text from the filing

With the appointment of Mr. Talamo as the Company’s new Chief Financial Officer, Mr. Wesolowski will no longer serve in this capacity but will continue on as the Company’s Principal Accounting Officer and Controller.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Joseph Talamo was appointed as Chief Financial Officer at INTENSITY THERAPEUTICS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On December 11, 2023, Intensity Therapeutics (the “Company”), appointed Joseph Talamo to serve as the Chief Financial Officer of the Company effective December 11, 2023.

View on SEC.gov

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-094884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.